HomeCompareENZB vs VYM

ENZB vs VYM: Dividend Comparison 2026

ENZB yields 57.24% · VYM yields 2.41%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENZB wins by $540.6K in total portfolio value
10 years
ENZB
ENZB
● Live price
57.24%
Share price
$0.70
Annual div
$0.40
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$568.4K
Annual income
$128,106.33
Full ENZB calculator →
VYM
Vanguard High Dividend Yield ETF
● Live price
2.41%
Share price
$145.48
Annual div
$3.51
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$278.55
Full VYM calculator →

Portfolio growth — ENZB vs VYM

📍 ENZB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENZBVYM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENZB + VYM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENZB pays
VYM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENZB
Annual income on $10K today (after 15% tax)
$4,865.00/yr
After 10yr DRIP, annual income (after tax)
$108,890.38/yr
VYM
Annual income on $10K today (after 15% tax)
$205.23/yr
After 10yr DRIP, annual income (after tax)
$236.77/yr
At 15% tax rate, ENZB beats the other by $108,653.61/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENZB + VYM for your $10,000?

ENZB: 50%VYM: 50%
100% VYM50/50100% ENZB
Portfolio after 10yr
$298.1K
Annual income
$64,192.43/yr
Blended yield
21.53%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ENZB right now

ENZB
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-5.0
Piotroski
3/9
VYM
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENZB buys
0
VYM buys
1
PoliticianChamberTickerTypeAmountDate
Carol Devine Miller🏢 House$VYM▲ Buy$15,001 - $50,0002022-11-02
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENZBVYM
Forward yield57.24%2.41%
Annual dividend / share$0.40$3.51
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$568.4K$27.8K
Annual income after 10y$128,106.33$278.55
Total dividends collected$467.0K$2.6K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: ENZB vs VYM ($10,000, DRIP)

YearENZB PortfolioENZB Income/yrVYM PortfolioVYM Income/yrGap
1← crossover$16,424$5,723.53$11,151$241.44+$5.3KENZB
2$26,358$8,785.09$12,413$246.79+$13.9KENZB
3$41,380$13,176.89$13,794$251.79+$27.6KENZB
4$63,610$19,333.26$15,306$256.47+$48.3KENZB
5$95,838$27,775.03$16,960$260.84+$78.9KENZB
6$141,656$39,109.45$18,768$264.92+$122.9KENZB
7$205,597$54,025.12$20,745$268.71+$184.9KENZB
8$293,270$73,281.42$22,905$272.24+$270.4KENZB
9$411,492$97,692.52$25,265$275.51+$386.2KENZB
10$568,402$128,106.33$27,842$278.55+$540.6KENZB

ENZB vs VYM: Complete Analysis 2026

ENZBStock

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Full ENZB Calculator →

VYMETF

Seeks to track the performance of the FTSE High Dividend Yield Index, which measures the investment return of common stocks of companies characterized by high dividend yields. Provides a convenient way to track the performance of stocks that are forecasted to have above-average dividend yields. Follows a passively managed, full-replication approach.

Full VYM Calculator →
📬

Get this ENZB vs VYM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENZB vs SCHDENZB vs JEPIENZB vs OENZB vs KOENZB vs MAINENZB vs VIGENZB vs DGROENZB vs HDV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.